FILING ANALYSIS · MONDAY, OCTOBER 5
AbbVie Inc. ABBV — 8-K: Results of Operations and Financial Condition
neutral
AbbVie's adjusted diluted EPS guidance for Q3 2026 is $3.73-$3.77, and full-year 2026 guidance is $13.76-$13.96, including the impact of acquired IPR&D and milestones expense, which is expected to be $216 million for Q3 2026, representing an unfavorable impact of $0.11 to both GAAP diluted EPS and adjusted non-GAAP diluted EPS.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →